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Glycogen storage disease type IV (GSD-IV) is an au-
tosomal recessive disease caused by a deficient gly-
cogen branching enzyme (GBE), encoded by the 
GBE1 gene, resulting in the accumulation of abnormal 
glycogen deposits in the liver and other tissues. We 
treated a 20-month-old girl who presented with pro-
gressive liver cirrhosis and was diagnosed with 
GSD-IV, as confirmed by GBE1 gene mutation analy-
sis, and underwent living related heterozygous donor 
liver transplantation. Direct sequencing of the GBE1 
gene revealed that the patient was compound hetero-
zygous for a known c.1571G＞A (p.Gly264Glu) muta-
tion a novel c.791G＞A (Arg524Gln) mutation. This is 
the first report of a Korean patient with GSD-IV con-
firmed by mutation analysis, who was treated suc-
cessfully by liver transplantation. (Gut and Liver 
2009;3:60-63)
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INTRODUCTION
  Glycogen storage disease type IV (GSD-IV, Andersen 
disease: OMIM 232500) is a rare autosomal recessive dis-
order caused by deficient glycogen branching enzyme 
(GBE) activity.1 This deficiency leads to the accumulation 
of amylopectin-like glycogen (polyglucosan), which has 
fewer branching points and longer outer chains than nor-
mal glycogen, and results in variable clinical presenta-
tions, including hepatic and neuromuscular forms.2 
GSD-IV has been diagnosed histologically and biochemi-
cally, by measuring glycogen branching enzymes in in-
dividual tissues.3 GSD-IV is associated with mutations in 
GBE1, which encodes the glycogen branching enzyme,4 
and several types of GBE1 mutation have been 
identified.5,6 We describe here a 20 month-old girl with 
progressive liver cirrhosis associated with GSD-IV, as con-
firmed by GBE1 gene analysis, who was successfully treat-
ed by liver transplantation. 
CASE REPORT
  A 20 month-old girl initially visited a tertiary hospital 
with hepatosplenomegaly. She was born at 37 weeks ges-
tation by vaginal delivery and her birth weight was 2,470 
g. On admission, her body weight was 11 kg (25th-50th 
percentile) and height was 79 cm (25th-50th percentile). 
Her blood pressure was 97/53 mmHg, heart rate 122 
beats per min, respiratory rate 28 breaths per min, and 
body temperature was 36.5oC. On physical examination, 
sclera was icteric and the liver was hard and palpable by 
two fingerbreadth below the rib. The spleen was also pal-
pable by two fingerbreadth below the rib, and abdomen 
was distended without ascites. Neurologic examination 
showed no definite abnormality and muscle tone was ap-
propriate for her age. Laboratory tests showed hemoglo-
bin 10 g/dL, white blood cell count 9,000/mm3 (neutro-
phils 69%, lymphocytes 23%, monocytes 7%, eosinophils 
1%), platelet count 149,000/mm3, total protein 6.8 g/dL, 
albumin 3.2 g/dL, aspartate aminotransferase 542 IU/L, 
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Fig. 1. Microscopic features on H&E staining (A) and electron microscopy (B, C) of a liver biopsy sample. The hepatocytes 
contained pale pink cytoplasmic amorphous material (H&E stain, ×200) (A). These intracytoplasmic inclusions consisted of 
randomly oriented delicate fibrils that were up to 5 nm in diameter (B, C). 
Fig. 2. GBE1 mutations in a Korean patient with glycogen storage disease type IV. Mutations in GBE1 are shown by sequence traces 
from patient DNA. Arrows indicate the exons containing mutations, which consisted of a known missense mutation (upper, 
c.1571G＞A) in exon 12 and a novel missense mutation (bottom, c.791G＞A) in exon 7.
alanine aminotransferase 229 IU/L, total bilirubin 5 
mg/dL, direct bilirubin 2.9 mg/dL, gamma-glutamyltrans-
peptidase 94 IU/L, alkaline phosphatase 299 IU/L, pro-
thrombin time 47.3% (1.52 INR), and activated partial 
thrombin time 34.3 sec. Serologic markers for hepatitis A 
virus, hepatitis B virus, hepatitis C virus, Epstein-Barr vi-
rus, and cytomegalovirus were negative. A chest X-ray 
showed mild cardiomegaly. Hematoxylin-eosin (H&E) 
staining of a liver biopsy showed micronodular cirrhosis 
with colorless or pale eosinophilic cytoplasmic inclusions 
in hepatocytes and histiocytes, findings consistent with 
glycogen storage disease, type IV (Fig. 1A). Therapy with 
cornstarch was commenced but the patient showed pro-
gression of liver cirrhosis. She was therefore transferred 
to the Asan Medical Center for liver transplantation. At 
Asan Medical Center, physical examination showed hep-
atosplenomegaly with distension and newly developed 
ascites. Echocardiography revealed mild left ventricular 
hypertrophy. 
  Molecular genetic analysis of the GBE1 gene was 
performed. Direct sequencing of the 22 exons and the 
exon-intron boundaries of the GBE1 gene on chromosome 
3p12 using DNA isolated from peripheral blood showed 
that the patient was compound heterozygous for a known 
mutation, c.1571G＞A (p.Gly264Glu), and a novel muta-
tion c.791G＞A (Arg524Gln) (Fig. 2).
  At 27 months of age, she underwent living donor liver 
transplantation from her father, a heterozygous donor. 
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The transplant was uneventful. The explanted liver, which 
measured 19×12×5.5 cm and weighed 593 gm, had a 
shrunken appearance and was diffusely nodular with a 
brownish green color. Microscopic examination revealed 
variable-sized regenerating nodules, supporting the diag-
nosis of cirrhosis. The morphologic features of the hep-
atocytes were identical with those observed in the pre-
vious liver biopsy (Fig. 1A). The intracytoplasmic in-
clusions were strongly positive on periodic acid-Schiff 
(PAS) staining, but were resistant to diastase, excluding 
other types of glycogen storage disease. Electron micro-
scopy demonstrated that the cytoplasmic inclusions con-
tained undulating, randomly-oriented, delicate fibrils, con-
firming the diagnosis of glycogen storage disease type IV 
(Fig. 1B, C). 
  Following liver transplantation, the patient was treated 
with standard immunosuppressive therapy. Six months af-
ter transplantation, she is well, with normal liver func-
tion, growth and development. However, mild car-
diomegaly on a chest X-ray and mild left ventricular hy-
pertrophy on echocardiography still persisted without 
change.
DISCUSSION
  Glycogen storage diseases are over 12 types and they 
are classified based on the enzyme deficiency and affected 
tissue. In Korea, GSD-Ia was first reported in 1972 and 
GSD-IV was firs reported in 1998.3,7
  Our patient presented with features typical of GSD-IV,1 
including failure to thrive, hepatosplenomegaly, and pro-
gressive liver cirrhosis, which, if left untreated, leads to 
death before the age of 5 years. Milder nonprogressive 
hepatic forms of GSD-IV have also been described, but 
they are less frequent.8 In addition to hepatic forms of 
GSD-IV, various neuromuscular forms are known, which 
differ according to age at onset and severity; these include 
fatal perinatal, congenital, childhood, and adult forms,5 
which present with symptoms of myopathy, cardiopathy, 
and central and peripheral nervous system dysfunction. 
Our patient also showed mild cardiomegaly on chest 
X-ray and mild left ventricular hypertrophy on echo-
cardiography, suggesting myocardial involvement.
  All forms of GSD-IV result from molecular defects in 
GBE1, located on chromosome 3p12. GBE1 mutation anal-
ysis of a variety of patients suggests a genotype/pheno-
type correlation, with null mutations such as deletions, 
insertions, or nonsense mutations being associated with a 
more severe clinical phenotype.2,5,6 However, the geno-
type/phenotype correlation in this disease remains 
unclear. Our patient showed compound heterozygosity for 
the R524Q and G264E mutations. The R524Q mutation 
is known in patients with the milder hepatic form of 
GSD-IV,6 whereas G264E is a previously unreported 
mutation. This mutation clearly diminishes the GBE activ-
ity, but the pathogenic mechanism is not clear.9
  Diagnosis of GSD-IV includes the histologic detection 
of abnormal glycogen storage and the biochemical meas-
urement of deficient GBE activity, postnatally in red 
blood cells, leukocytes, hepatocytes, and cultured fibro-
blasts, and/or prenatally in amniotic fluid and chorionic 
villus cells.10,11 Although we could not measure enzyme 
activity to assist in diagnosis, we were able to detect ab-
normal glycogen storage in the liver and the GBE1 
mutations.
  As there is no way to replace the deficient enzyme ac-
tivity, liver transplantation is the only known treatment 
modality. The first successful liver transplantation for 
GSD-IV was performed in 1984.12 To date, only 17 pa-
tients have been reported to receive liver transplants for 
this condition, and most did not develop cardiopathy or 
myopathy.13 Three of these patients received transplants 
from living, related, heterozygous donors, as did our pa-
tient, and no mortality or morbidity related to hetero-
zygosity has yet been observed.14 Extrahepatic deposits of 
polyglucosan have been reported to be resorbed through 
the migration of donor cells (forming a microchimerism) 
from the liver allograft,15 although one patient died from 
cardiopathy after liver transplantation.16 Therefore, al-
though liver transplantation was successful in our patient, 
long-term follow-up is necessary to guard against neuro-
muscular complications. Identification of the specific GBE1 
mutations will facilitate genetic diagnosis of GSD-IV, and 
genetic counseling for this family, should there be future 
pregnancies.
  In conclusion, we report a patient diagnosed with 
GSD-IV by GBE1 mutation analysis, who underwent suc-
cessful liver transplantation from a heterozygous donor.
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